Strike Pharma AB is a biotechnology and pharmaceutical startup founded in 2020. The company's slogan, "Harnessing personalized medicine to target tumors and protect healthy cells, delivering cost-effective treatments with minimal side effects," encapsulates its focus on personalized medicine. This is achieved through the utilization of the unique Adaptable Drug Affinity Conjugate (ADAC) technology. The approach revolves around an antibody-based method customized to the genetic profile of each patient's tumor, effectively targeting and destroying cancer cells while sparing healthy ones, thereby reducing side effects.
In 22 February 2022, Strike Pharma secured a significant kr45.00M investment in a Venture Round. Notably, the investors in this round were Eir Ventures and Flerie Invest. This funding is expected to further the development and commercialization of its personalized medicine technology, potentially revolutionizing cancer treatment. As such, Strike Pharma AB has the potential to make a substantial impact in oncology through its innovative approach and disruptive technology.
